TrialSignal
Clinical trial intelligence report
A Phase IIb Randomized Double-Blinded Positive Controlled Trial to Evaluate the Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults Who Have Completed Two Doses of CoronaVac® or the mRNA Vaccine (Comirnaty) in Turkey
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT05150496-Jul 28, 2026
NCT ID
NCT05150496
Status
SUSPENDED
Phase
Phase 2b
Sponsor
Sinovac Research and Development Co., Ltd.
Executive brief
Investment-Ready Snapshot
The Phase IIb clinical trial for the CoronaVac® booster dose, sponsored by Sinovac Research and Development Co., Ltd., aims to evaluate the immunogenicity and safety of high and medium doses in healthy adults previously vaccinated with either CoronaVac® or Comirnaty. Given the ongoing global demand for COVID-19 vaccines and booster doses, this trial positions Sinovac to potentially enhance its market share in Turkey and other regions. The competitive landscape includes mRNA vaccines and other inactivated vaccines, necessitating a focus on demonstrating superior immunogenicity and safety profiles to maintain a competitive edge. The trial's suspension due to a change in plans may impact timelines and investor confidence, warranting close monitoring of future developments.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05150496
Indication
COVID-19
Modality
vaccine
Target
SARS-CoV-2 virus (inactivated vaccine)
Intervention
Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated, High-dose COVID-19 Vaccine(Vero Cell),Inactivated
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.